Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 114 | 1 | 114 | +1 |
| Shares | 55.4M | 39.7K | 58.1M | +2.75M (+5.0%) |
| Value | $588.2M | $421.4K | $598.6M | +$10.7M (+1.8%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Portolan Capital Management, LLC | 1,130,089 | $11.6M | 0.96% |
| Prudential Financial Inc | 352,340 | $3.63M | 0.01% |
| Oracle Investment Management Inc | 225,000 | $2.32M | 2.49% |
| Marshall Wace, LLP | 112,691 | $1.16M | 0.00% |
| MML Investors Services, LLC | 19,600 | $202.0K | 0.00% |
| Brevan Howard Capital Management LP | 18,792 | $193.6K | 0.01% |
| Corebridge Financial, Inc. | 18,358 | $189.1K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 16,270 | $167.6K | 0.00% |
| Balyasny Asset Management LLC | 15,006 | $154.6K | 0.00% |
| LVW Advisors, LLC | 12,909 | $133.0K | 0.02% |
| Commonwealth Equity Services, LLC | 11,596 | $119.0K | 0.00% |
| Group One Trading, L.P. | 7,368 | $75.9K | 0.00% |
| Russell Investments Group, Ltd. | 520 | $5.36K | 0.00% |
| Aquatic Capital Management LLC | 500 | $5.15K | 0.00% |
| Bessemer Group Inc | 325 | $3.00K | 0.00% |
| Comerica Bank | 129 | $1.33K | 0.00% |
| Rothschild Investment LLC | 20 | $206 | 0.00% |
| SRS Capital Advisors, Inc. | 17 | $176 | 0.00% |
Sold out (17)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Octagon Capital Advisors LP | 455,000 | $4.83M |
| Millennium Management LLC | 225,024 | $2.39M |
| Newtyn Management, LLC | 165,000 | $1.75M |
| D. E. Shaw & Co., Inc. | 64,138 | $681.1K |
| Susquehanna International Group, LLP | 59,437 | $631.2K |
| UBS Oconnor LLC | 28,583 | $303.6K |
| Prelude Capital Management, LLC | 22,044 | $234.1K |
| Jacobs Levy Equity Management, Inc | 20,987 | $222.9K |
| SG Americas Securities, LLC | 18,873 | $200.0K |
| American International Group, Inc. | 15,802 | $167.8K |
| Entropy Technologies, LP | 12,138 | $128.9K |
| Principal Financial Group Inc | 10,783 | $114.5K |
| State Board of Administration of Florida Retirement System | 11,228 | $80.2K |
| Metropolitan Life Insurance Co | 1,818 | $19.3K |
| ICA Group Wealth Management, LLC | 1,300 | $13.8K |
| Vestcor Inc | 548 | $6.00K |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 7 | $74 |
Not filed for Q2 2024 yet (1)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 39,683 | $421.4K |